Diallyl sulfide enhances azoxymethane-induced preneoplasia in Fischer 344 rat colon.
Azoxymethane (AOM) is an indirect-acting colon carcinogen that produces a high incidence of precancerous lesions, referred to as aberrant crypt foci (ACF), in rats. This study was undertaken to determine whether high dose gavage administration of the cytochrome P-450 2E1 (CYP2E1) inhibitor and chemopreventive agent, diallyl sulfide, would reduce the incidence and severity of ACF formation in the distal colons of AOM-treated Fischer 344 rats. Seven-week-old male rats received 150 or 50 mg/kg diallyl sulfide by gavage 24 and 2 h prior to two weekly i.p. injections of AOM (20 mg/kg). Ten weeks after the last injection of AOM the rats were sacrificed and the colons removed and stained with 0.2% methylene blue. ACF were visualized using stereomicroscopy. Rats pretreated with diallyl sulfide exhibited a significant increase in the number of ACF/cm in the distal colon compared with rats receiving AOM alone. This increase in ACF number was seen in ACF of all sizes. To examine the effects of diallyl sulfide on the initiation stage of AOM-induced carcinogenesis, mutations in the K-ras proto-oncogene were also investigated. ACF and normal appearing colonic mucosa (0.2-0.5 mm3) were microdissected for subsequent PCR-RFLP analysis of a codon 12 (GGT-GGA) activating mutation in the K-ras gene. Greater than 90% of ACF from AOM-treated animals, regardless of diallyl sulfide treatment, exhibited activating K-ras mutations. K-ras mutations were also detected in normal appearing mucosa of AOM-treated animals, although at a lesser frequency (15-35%). These studies demonstrate that diallyl sulfide given in large gavage doses enhances AOM-induced preneoplasia in rats and suggests that diallyl sulfide may alter the disposition of AOM intermediates and/or enhance colonic promotional activity in the rat.
Delker
D A
DA
Toxicology Program, University of Connecticut, Storrs 06269, USA.
Papanikolaou
A
A
Suhr
Y J
YJ
Rosenberg
D W
DW
D000498:Allyl Compounds / Q000627:therapeutic use / Q000633:toxicity*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use / Q000633:toxicity*; D001391:Azo Compounds / Q000633:toxicity*; D002273:Carcinogens / Q000633:toxicity*; D003110:Colonic Neoplasms / Q000139:chemically induced* / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000633:toxicity; D011905:Genes, ras / Q000187:drug effects / Q000235:genetics; D008297:Male; D009154:Mutation; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D011230:Precancerous Conditions / Q000139:chemically induced* / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control; D051381:Rats; D011916:Rats, Inbred F344; D013440:Sulfides / Q000627:therapeutic use / Q000633:toxicity*
D000498:Allyl Compounds; D016588:Anticarcinogenic Agents; D001391:Azo Compounds; D002273:Carcinogens; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D004791:Enzyme Inhibitors; D013440:Sulfides; C001825:azomethane; C038491:allyl sulfide